Table I.
Parameter | SCC25 | CAL27 | FaDu | 2D:3D | P-value |
---|---|---|---|---|---|
Ki-67 | |||||
2D | 2.7 | 2.5 | 2.3 | 3.2 | 0.0134 |
3D | 0.7 | 0.7 | 1.0 | ||
VEGFR | |||||
2D | 2.5 | 2.8 | 2.0 | 1.2 | 0.7289 |
3D | 3.0 | 1.5 | 1.5 | ||
EGFR | |||||
2D | 2.8 | 1.0 | 2.3 | 0.7 | 0.4460 |
3D | 3.0 | 3.0 | 2.8 | ||
Survivin | |||||
2D | 2.8 | 2.8 | 3.0 | 1.1 | 0.0595 |
3D | 2.6 | 2.6 | 3.0 |
Samples were categorized to one of four expression levels: 0, <5%; 1 (weak), 5–30%; 2 (moderate), 30–60%; and 3 (strong), 60–100%, and then an average expression score was calculated. VEGFR, vascular endothelial growth factor receptor; EGFR, epidermal growth factor receptor; 2D, two-dimensional; 3D, three-dimensional.